title: Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.
abstract: Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like (131)I or (90)Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of (90)Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as (90)Y, (177)Lu, (131)I, (124)I, and (188)Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). (90)Y and (188)Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.
authors.affiliation: Research Centre for the Physics of Matter and Radiation (PMR), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium ; NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Lucas
authors.affiliation: Pharmacology and Therapeutics Unit (FATH), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCL), 53 Avenue Mounier, 1200 Brussels, Belgium.
authors.forename: O
authors.initials: O
authors.lastname: Feron
authors.affiliation: Biomedical Magnetic Resonance Group (REMA), Louvain Drug Research Institute, Université Catholique de Louvain (UCL), 73 Avenue Mounier, 1200 Brussels, Belgium.
authors.forename: B
authors.initials: B
authors.lastname: Gallez
authors.affiliation: NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium ; Namur Medicine and Drug Innovation Center (NAMEDIC), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium.
authors.forename: B
authors.initials: B
authors.lastname: Masereel
authors.affiliation: NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium ; Unité de Recherche en Biologie Cellulaire (URBC), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Michiels
authors.affiliation: NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium ; Centre for Molecular Imaging, Radiotherapy and Oncology (MIRO), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCL), 1 Dr. G. Therasse, 5530 Yvoir, Belgium.
authors.forename: T
authors.initials: T
authors.lastname: Vander Borght
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy; D003198:Computer Simulation; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008168:Lung / Q000528:radiation effects; D008175:Lung Neoplasms / Q000532:radiotherapy; D008187:Lutetium / Q000627:therapeutic use; D015233:Models, Statistical; D009010:Monte Carlo Method; D050997:Nanomedicine / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000532:radiotherapy*; D017564:Radiation Pneumonitis / Q000175:diagnosis; D016499:Radioimmunotherapy / Q000295:instrumentation* / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use*; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods; D012211:Rhenium / Q000627:therapeutic use; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D015021:Yttrium Radioisotopes; D008187:Lutetium; D012211:Rhenium